Arad; Gila

Patent Applications and Registrations

Patent applications and USPTO patent grants for Arad; Gila.The latest application filed is for "peptides for use in the treatment of viral infections".

Company Profile

1.9.9

Arad; Gila - Mevasseret Zion IL
Arad; Gila - Jerusalem IL
Arad; Gila - Jersualem IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Peptides for use in the treatment of viral infections Grant 11,304,989 - Kaempfer , et al. April 19, 2	2022-04-19
Peptides For Use In The Treatment Of Viral Infections App 20200276262 - KAEMPFER; Raymond ; et al.	2020-09-03
Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 Grant 10,280,209 - Kaempfer , et al.	2019-05-07
Reduction Of Inflammatory Disease Symptoms By Short Peptides That Inhibit Signaling Through Cd28 App 20180215804 - KAEMPFER; Raymond ; et al.	2018-08-02
Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 Grant 9,963,497 - Kaempfer , et al. May 8, 2	2018-05-08
Synthetic peptides for treatment of bacterial infections Grant 9,567,367 - Shirvan , et al. February 14, 2	2017-02-14
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof Grant 9,546,207 - Kaempfer , et al. January 17, 2	2017-01-17
Reduction Of Inflammatory Disease Symptoms By Short Peptides That Inhibit Signaling Through Cd28 App 20160289295 - KAEMPFER; Raymond ; et al.	2016-10-06
Synthetic Peptides For Treatment Of Bacterial Infections App 20140336359 - Shirvan; Anat ; et al.	2014-11-13
Broad-spectrum In-vivo Effective Superantigen Toxin Antagonists Based On The Interaction Between Cd28 And The Superantigen And Uses Thereof App 20140011731 - Kaempfer; Raymond ; et al.	2014-01-09
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof Grant 8,535,672 - Kaempfer , et al. September 17, 2	2013-09-17
Broad spectrum pyrogenic exotoxins antagonists and vaccines Grant 7,189,398 - Kaempfer , et al. March 13, 2	2007-03-13
Broad spectrum pyrogenic antagonists and vaccines directed against pyrogenic exotoxins App 20060222650 - Kaempfer; Raymond ; et al.	2006-10-05
Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins Grant 7,060,277 - Kaempfer , et al. June 13, 2	2006-06-13
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof App 20050191296 - Kaempfer, Raymond ; et al.	2005-09-01
Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins App 20030147908 - Kaempfer, Raymond ; et al.	2003-08-07
Broad Spectrum Pyrogenic Exotoxins Antagonists And Vaccines App 20020028211 - KAEMPFER, RAYMOND ; et al.	2002-03-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.